# Clostridium difficile Colitis

---

## I. Purpose

Clostridium difficile infection (CDI) is an increasingly common cause of nosocomial morbidity and mortality from the gram-positive, spore-forming anaerobic bacillus. Up to 30% of patients with fulminant CDI require urgent surgery, and there is a >40% mortality rate in those requiring emergency surgery. Prompt recognition and treatment are therefore paramount.

---

## II. Guideline

### A. Initial Evaluation

- **Clinical suspicion for CDI**
    
    * Recent healthcare facility exposure  
    * Recent antibiotic use (especially clindamycin)  
    * >3 unformed stools in 24 hours without laxatives  
    * Consider tube feeds as a cause of diarrhea if applicable

- **Labs**
    
    * CBC  
    * BMP  
    * *C. difficile PCR with Reflex Toxin Panel*  
        * PCR negative → C. difficile not present  
        * PCR positive/Toxin positive → **Treat**  
        * PCR positive/Toxin negative → Likely colonized, treatment based on clinical picture:  
            - Does the patient have >3 risk factors?  
            - Have alternative causes of diarrhea been ruled out?  
            - Are symptoms/WBC/vitals worsening off therapy?

- **Imaging**
    
    * Consider CT Abdomen/Pelvis with IV contrast for suspected severe or fulminant CDI

- **Evaluation of Severity**
    
    * **Nonsevere CDI**
        - HR < 90 bpm, SBP > 100 mmHg  
        - Tmax < 101.5°F  
        - WBC < 15,000  
        - Normal lactate  
        - Oliguria responsive to fluids  
        - Mild abdominal tenderness

    * **Severe CDI**
        - HR > 90 bpm without hypotension  
        - Fever > 101.5°F  
        - WBC > 15,000  
        - Creatinine > 1.5 mg/dL  
        - Moderate abdominal tenderness

    * **Fulminant CDI**
        - Shock with hypotension  
        - Need for vasopressors  
        - Ventilator dependence  
        - Oliguria unresponsive to fluids  
        - Perforation  
        - Toxic megacolon (cecal diameter >12 cm or colon diameter >6 cm)

---

### B. Antibiotic Therapy

- **Nonsevere CDI**
    
    * Vancomycin 125 mg PO q6h x 10 days  
    * *OR* Fidaxomicin 200 mg PO BID x 10 days (for high-risk patients)

- **Severe CDI**
    
    * Vancomycin 125 mg PO q6h x 10 days  
    * *OR* Fidaxomicin 200 mg PO BID x 10 days (for high-risk patients)

- **Fulminant CDI**
    
    * Vancomycin 500 mg PO q6h **PLUS** Metronidazole 500 mg IV q8h  
    * If ileus (no megacolon): Add Vancomycin 500 mg PR q6h

- **Recurrent CDI**
    
    * **First recurrence:** Fidaxomicin 200 mg PO BID x 10 days  
    * **Multiple recurrences:**  
        - Infectious Disease (ID) consult  
        - Fidaxomicin 200 mg PO BID x 10 days  
        - Vancomycin taper  
        - Vancomycin followed by Rifaximin

- **High-risk features** (≥3 of the following):
    
    * Recent high-risk antibiotics (fluoroquinolones, clindamycin, carbapenems, 3rd/4th gen cephalosporins)  
    * Healthcare exposure (past 12 weeks)  
    * Age > 65  
    * Chronic gastric acid suppression  
    * Solid organ transplant  
    * Hematopoietic stem cell transplant  
    * Chemotherapy  
    * CKD or ESRD  
    * Prolonged hospitalization  
    * Recent GI procedure

- **Fidaxomicin limitations**
    
    * Do **not** use if PCR+/Toxin-  
    * Requires ID attending approval (page 317-4376)  
    * Confirm affordability prior to discharge

---

### C. Indications for Surgical Management

- **Key principle:** Preoperative physiologic status is the strongest predictor of postoperative mortality  
- **Strongly consider TAC with end ileostomy (TAC/EI)** if:
    
    * Severe colonic distension  
    * Clinical deterioration despite maximal medical therapy (within 24–48h)  
    * Pneumatosis  
    * Impending perforation

---

### D. Postoperative Management of TAC/EI

- Consider pelvic drain (based on rectal stump quality)
- ICU admission strongly recommended
- **Antibiotic therapy post-op**
    
    * No clear guidelines exist  
    * If perforation: consider 4-day course of abdominal sepsis antibiotics  
    * Continue Vancomycin 500 mg PO q6h or Metronidazole 500 mg IV q8h x 7 days (until bowel function returns)

---

## III. References

1. McDonald LC, et al. *Clin Infect Dis.* 2018;66(7):e1–e48. doi:10.1093/cid/cix1085  
2. Johnson S, et al. *Clin Infect Dis.* 2021  
3. Cornely OA, et al. *Lancet Infect Dis.* 2012;12(4):281–289. doi:10.1016/S1473-3099(11)70374-7  
4. Van der Wilden G, et al. *Surg Infect.* 2015  
5. Seltman A. *Clin Colon Rectal Surg.* 2012  
6. Choron R, Lipsett P. In: *Current Surgical Therapy,* 13th Ed. 2020  
7. Kelly CR, et al. *Am J Gastroenterol.* 2021;116(6):1124–1147  
8. Vanderbilt Antimicrobial Stewardship Program. [CDI Guidelines](https://vumc365.sharepoint.com/sites/TheDreamTeam792/Shared%20Documents/General/Guidelines/CDI%20Guidelines%20Final.pdf)

---

## IV. Authors

- Michael J. Derickson, MD  
- Joshua J. Thompson, MD, PhD  
- Jade Flynn, PharmD, BCPS  

*July 22, 2024*
